clinical trial · NCT02393625
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
ALK-positive NSCLCCeritinib (LDK378)Nivolumab
brief summary
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
started
May 27, 2015
primary completion
Apr 9, 2027
completion
Apr 9, 2027
last updated
Jun 11, 2026
official title
A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol